2023
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
Allanore Y, Khanna D, Smith V, Aringer M, Hoffmann-Vold A, Kuwana M, Merkel P, Stock C, Sambevski S, Denton C, Bergna M, Casado G, Walter P, Proudman S, Stevens W, Thakkar V, Troy L, Loeffler-Ragg J, Olschewski H, André B, Bondue B, Houssiau F, Smith V, Wuyts W, Azevedo V, Johnson S, Keystone E, Khalidi N, Levesque M, Rozas R, Orellana A, Huang C, Li J, Jiang Z, Liu Y, Xiao W, Xu J, Zeng X, Zheng Y, Zou H, Becvar R, Madsen H, Søndergaard K, Kilpeläinen M, Myllärniemi M, Agard C, Allanore Y, Bourdin A, Cottin V, Crestani B, Diot E, Dominique S, Hachulla E, Jouneau S, Leroy S, Nunes H, Prevot G, Wallaert B, Wemeau L, Aringer M, Bewig B, Blaas S, Distler J, Ehrchen J, Ewert R, Gläser S, Henes J, Hunzelmann N, König R, Kötter I, Kreuter M, Prasse A, Schulze-Koops H, Sfikakis P, Vlachoyiannopoulos P, Losonczy G, Behera D, Devi H, Kadel J, Kawedia M, Kumar D, Kumar U, Lokhande R, Malpani A, Mohan M, Nalawade A, Parakh U, Swarnakar R, Shobha V, Thangakunam B, Udwadia Z, Henry M, O'Reilly K, Balbir-Gurman A, Kramer M, Litinsky I, Rosner I, Cutolo M, Gabrielli A, Iaccarino L, Pesci A, Riccieri V, Vettori S, Funakubo Y, Inoue Y, Kawakami A, Kawaguchi Y, Kawamura T, Kondoh Y, Kuwana M, Nanki T, Nishioka Y, Nozawa K, Ogura T, Okamoto M, Sano H, Sasai R, Sasaki N, Suda T, Takahashi H, Takeuchi T, Makino S, Tanaka S, Yamasaki Y, Ch'ng S, Cheah C, Kan S, Mohamed R, Selman M, de Vries-Bouwstra J, van den Toorn L, Vonk M, Voskuyl A, Hoffmann-Vold A, Seip M, Dankiewicz-Fares I, Olesiejuk R, Pulka G, Szepietowski J, Alves J, Bernardes M, Cordeiro A, Costa J, Neves S, Salvador M, Sancho J, Delgado P, Barranco I, Martínez J, del Castillo A, Ovalles J, López-Longo F, Gallego A, Dapena M, Ivorra J, Ekwall A, Maurer B, Mihai C, Müller R, Mahakkanukrauh A, Nantiruj K, Siripaitoon B, Denton C, Herrick A, Madhok R, Maher T, West A, Antin-Ozerkis D, Bascom R, Criner G, Csuka M, D'Amico J, Ettinger N, Fischer A, Gerbino A, Gerke A, Glassberg M, Glazer C, Golden J, Gripaldo R, Gupta N, Hamblin M, Highland K, Ho L, Huggins J, Hummers L, Jones L, Kahaleh M, Khanna D, Kim H, Lancaster L, Luckhardt T, Mayes M, Ballesteros F, Mooney J, Mohabir P, Morrissey B, Moua T, Padilla M, Patel N, Perez R, Roman J, Rossman M, Russell T, Saketkoo L, Shah A, Shlobin O, Scholand M, Simms R, Spiera R, Steen V, Veeraraghavan S, Weigt S. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. Rheumatology 2023, 63: 639-647. PMID: 37294870, PMCID: PMC10907814, DOI: 10.1093/rheumatology/kead280.Peer-Reviewed Original ResearchLimited cutaneous systemic sclerosisInterstitial lung diseaseCutaneous systemic sclerosisSENSCIS trialEffect of nintedanibWeek 52Nintedanib groupPlacebo groupSystemic sclerosisLung diseaseProgressive fibrosing interstitial lung diseasesOpen-label nintedanibSSc-ILDLung functionPulmonary fibrosisNintedanibPatientsRate of declineFVCTrialsPlaceboSclerosisDiseaseGroupFibrosis
2019
Omega-3 Fatty Acids and Genome-Wide Interaction Analyses Reveal DPP10–Pulmonary Function Association
Xu J, Gaddis N, Bartz T, Hou R, Manichaikul A, Pankratz N, Smith A, Sun F, Terzikhan N, Markunas C, Patchen B, Schu M, Beydoun M, Brusselle G, Eiriksdottir G, Zhou X, Wood A, Graff M, Harris T, Ikram M, Jacobs D, Launer L, Lemaitre R, O’Connor G, Oelsner E, Psaty B, Vasan R, Rohde R, Rich S, Rotter J, Seshadri S, Smith L, Tiemeier H, Tsai M, Uitterlinden A, Voruganti V, Xu H, Zilhão N, Fornage M, Zillikens M, London S, Barr R, Dupuis J, Gharib S, Gudnason V, Lahousse L, North K, Steffen L, Cassano P, Hancock D. Omega-3 Fatty Acids and Genome-Wide Interaction Analyses Reveal DPP10–Pulmonary Function Association. American Journal Of Respiratory And Critical Care Medicine 2019, 199: 631-642. PMID: 30199657, PMCID: PMC6396866, DOI: 10.1164/rccm.201802-0304oc.Peer-Reviewed Original ResearchMeSH KeywordsAgedalpha-Linolenic AcidBiomarkersDipeptidyl-Peptidases and Tripeptidyl-PeptidasesDocosahexaenoic AcidsEicosapentaenoic AcidFatty Acids, Omega-3Fatty Acids, UnsaturatedFemaleForced Expiratory VolumeGenome-Wide Association StudyHumansMaleMiddle AgedPolymorphism, Single NucleotideRespiratory Physiological PhenomenaSex FactorsSmokingVital CapacityConceptsSNP associationsGenome-wide interaction analysisHeart and Aging ResearchMeta-analysesCohort-specific resultsAssociated with lower FVCGenome-wide analysisGenomic Epidemiology ConsortiumAssociated with FEV<sub>1</sub> anPulmonary function testsEpidemiology ConsortiumFatty acidsEffect modificationFunctional associationN-3 PUFAPulmonary healthLower FVCGenetic susceptibilitySpirometric measurementsCohortPolyunsaturated fatty acidsAssociationMeasures of pulmonary function testsInteraction analysisFVC
2018
Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis
Showalter K, Hoffmann A, Rouleau G, Aaby D, Lee J, Richardson C, Dematte J, Agrawal R, Chang RW, Hinchcliff M. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis. The Journal Of Rheumatology 2018, 45: 1572-1576. PMID: 30275265, PMCID: PMC6214765, DOI: 10.3899/jrheum.171362.Peer-Reviewed Original ResearchConceptsScl-70 autoantibodiesPulmonary function testsNegative predictive valueInterstitial lung diseaseSSc-ILDVital capacityLung diseaseSystemic sclerosis-associated interstitial lung diseaseRadiographic interstitial lung diseaseHigh negative predictive valueReceiver-operating characteristic curveForced Vital CapacityILD evaluationChest HRCTSystemic sclerosisFunction testsTomography scanAmerican CollegeFVCDLCOPatientsAutoantibodiesPredictive valueSSc criteriaThoracic radiologists
2012
The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic Sclerosis
Peljto AL, Steele MP, Fingerlin TE, Hinchcliff ME, Murphy E, Podlusky S, Carns M, Schwarz M, Varga J, Schwartz DA. The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic Sclerosis. CHEST Journal 2012, 142: 1584-1588. PMID: 22576636, PMCID: PMC3515031, DOI: 10.1378/chest.12-0110.Peer-Reviewed Original ResearchConceptsInterstitial pneumoniaSystemic sclerosisPromoter polymorphismDistinct genetic risk factorsMUC5B Promoter PolymorphismUnaffected control subjectsGenetic risk factorsReticular infiltratesLung involvementControl subjectsRisk factorsIP diagnosisSporadic formsSecondary analysisFVCPneumoniaSclerosisCommon variantsConservative definitionPhenotypic heterogeneitySubjectsMinor allele frequencyPolymorphismAllele frequenciesAssociation
2009
The Ratio of FEV1 to FVC as a Basis for Establishing Chronic Obstructive Pulmonary Disease
Vaz Fragoso CA, Concato J, McAvay G, Van Ness PH, Rochester CL, Yaggi HK, Gill TM. The Ratio of FEV1 to FVC as a Basis for Establishing Chronic Obstructive Pulmonary Disease. American Journal Of Respiratory And Critical Care Medicine 2009, 181: 446-451. PMID: 20019341, PMCID: PMC3159085, DOI: 10.1164/rccm.200909-1366oc.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseFEV1/FVCObstructive pulmonary diseaseRisk of deathRespiratory symptomsPulmonary diseaseAdjusted hazard ratioRatio of FEV1Hazard ratioOdds ratioFVCClinical validityFifth percentileZ-scoreIdentifies personsSymptomsWhite personsDiseaseMeaningful outcomesDeathLambda-muPrevalenceRiskRepresentative sampleHigh threshold
2000
The Influence of Aging on Pulmonary Function Tests in Elderly Korean Population
Lee J, Kim E, Kang M, Son J, Lee S, Kim D, Park M, Lee M, Hyun I, Jung K. The Influence of Aging on Pulmonary Function Tests in Elderly Korean Population. Tuberculosis And Respiratory Diseases 2000, 49: 752-759. DOI: 10.4046/trd.2000.49.6.752.Peer-Reviewed Original ResearchPulmonary functional reservePulmonary function testsElderly Korean populationFunction testsFunctional reserveElderly populationMean FEV1Pulmonary functionMean FVCMean ageKorean populationChange of FVCPulmonary functional testsAge of patientsImprovement of nutritionGeographical residencyRespiratory symptomsIndependent factorsPredictive valueElderly personsFEV1FVCAged personsAgeMean height
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply